280 related articles for article (PubMed ID: 19258591)
1. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
Huo Y; McConnell SC; Ryan TM
Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
[TBL] [Abstract][Full Text] [Related]
2. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
Rivella S; May C; Chadburn A; Rivière I; Sadelain M
Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
[TBL] [Abstract][Full Text] [Related]
3. Humanized mouse models of Cooley's anemia: correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology.
Huo Y; McConnell SC; Liu S; Zhang T; Yang R; Ren J; Ryan TM
Ann N Y Acad Sci; 2010 Aug; 1202():45-51. PubMed ID: 20712771
[TBL] [Abstract][Full Text] [Related]
4. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.
Persons DA; Allay ER; Sabatino DE; Kelly P; Bodine DM; Nienhuis AW
Blood; 2001 May; 97(10):3275-82. PubMed ID: 11342459
[TBL] [Abstract][Full Text] [Related]
5. Humanized Mouse Model of Cooley's Anemia.
Huo Y; McConnell SC; Liu SR; Yang R; Zhang TT; Sun CW; Wu LC; Ryan TM
J Biol Chem; 2009 Feb; 284(8):4889-96. PubMed ID: 19098001
[TBL] [Abstract][Full Text] [Related]
6. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
8. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
Wilber A; Hargrove PW; Kim YS; Riberdy JM; Sankaran VG; Papanikolaou E; Georgomanoli M; Anagnou NP; Orkin SH; Nienhuis AW; Persons DA
Blood; 2011 Mar; 117(10):2817-26. PubMed ID: 21156846
[TBL] [Abstract][Full Text] [Related]
10. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
11. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
[TBL] [Abstract][Full Text] [Related]
12. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.
Puthenveetil G; Scholes J; Carbonell D; Qureshi N; Xia P; Zeng L; Li S; Yu Y; Hiti AL; Yee JK; Malik P
Blood; 2004 Dec; 104(12):3445-53. PubMed ID: 15292064
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
14. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
Hamed EM; Meabed MH; Aly UF; Hussein RRS
Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
[TBL] [Abstract][Full Text] [Related]
16. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
17. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
[TBL] [Abstract][Full Text] [Related]
18. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.
Bohl D; Bosch A; Cardona A; Salvetti A; Heard JM
Blood; 2000 May; 95(9):2793-8. PubMed ID: 10779423
[TBL] [Abstract][Full Text] [Related]
19. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
